NewsBenzingaBioCryst Pharma aumenta la guidance sulle vendite per l’anno fiscale 2026 da 690,000 milioni di dollari-715,000 milioni di dollari a 715,000 milioni di dollari-730,000 milioni di dollari rispetto a 710,134 milioni di dollari stimati BioCryst Pharma aumenta la guidance sulle vendite per l’anno fiscale 2026 da 690,000 milioni di dollari-715,000 milioni di dollari a 715,000 milioni di dollari-730,000 milioni di dollari rispetto a 710,134 milioni di dollari stimati Benzinga 2026.11.04 12:06 (GMT+0) Open on Benzinga Other news Key Overnight and Morning News (Nov 17 – Nov 18) Bitcoin, Ethereum Dip, While XRP, Dogecoin Gain as US Launches 'Self-Defense' Strikes Against Iran: Analyst Asks BTC Investors to 'Endure' Next 2 Months of Pain Global robotics company Genesis AI closes $500M Series A at $3.5B post-money valuation Alphabet's AI Drug Discovery Firm Isomorphic Labs Completes $5B Series C Funding, Co-Led by Sequoia Capital and Others Bitcoin miner MARA continues selling, offloading another $121 million in BTC over the past 8 days Jeff Bezos Warns Outsider CEO Replacing Jensen Huang Faces ‘Vanishingly Small Chance of Succeeding’ at Nvidia: ‘Too Complicated’
Bitcoin, Ethereum Dip, While XRP, Dogecoin Gain as US Launches 'Self-Defense' Strikes Against Iran: Analyst Asks BTC Investors to 'Endure' Next 2 Months of Pain
Alphabet's AI Drug Discovery Firm Isomorphic Labs Completes $5B Series C Funding, Co-Led by Sequoia Capital and Others
Jeff Bezos Warns Outsider CEO Replacing Jensen Huang Faces ‘Vanishingly Small Chance of Succeeding’ at Nvidia: ‘Too Complicated’